(Alliance News) - FTSE 100-listed AstraZeneca PLC on Tuesday reported positive results from the third phase of DAPA-HF trial.
The drugmaker said the study showed Farxiga met the primary composite endpoint with a reduction of cardiovascular death or the worsening of heart failure, compared to placebo.
Farxiga is an oral once-daily SGLT2 inhibitor, indicated as both monotherapy and as part of combination therapy, to improve glycaemic control, with the additional benefits of weight loss and blood-pressure reduction.
The trial was conducted in patients with reduced ejection fraction on standard of care treatment, including those with and without type-2 diabetes.
"With the DAPA-HF trial, Farxiga becomes the first in its class to demonstrate efficacy and safety data for the treatment of patients with heart failure, with and without type-2 diabetes, on top of standard of care," explained Mene Pangalos, executive vice president of biopharmaceuticals research & development unit at AstraZeneca.
Astrazeneca (AZN)